SOLICITATION NOTICE
B -- Services regarding The Family Study of Melanoma in Italy, Tissue Study Subgroup
- Notice Date
- 8/5/2005
- Notice Type
- Solicitation Notice
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-50119-NG
- Response Due
- 8/15/2005
- Archive Date
- 8/30/2005
- Description
- The National Cancer Institute (NCI), Genetic Epidemiology Branch (GEB), plans to procure on a sole source basis, for services regarding The Family Study of Melanoma in Italy, Tissue Study subgroup (02-C-N038), with Dr. Donato Calista, Department of Dermatology, Bufalini Hospital, Via Ex Tiro a Segno, 6, 47023 Cesena (FC), Italy. The supplies and services herein are commercial as defined in FAR Part 12, and are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13. The North American Industry Classification System code is 541710 and the business size standard is 500 employees. The Family Study of Melanoma in Italy, Tissue Study subgroup is conducted at the Maurizio Bufalini Hospital in Cesena, Italy. NCI proposes to conduct a series of expression and genetic studies on patients examined by Donato Calista, MD. Individuals with fair pigmentation, low tanning ability, germline mutations in susceptibility genes, and many melanocytic nevi or dysplastic nevi (DN), are at increased risk of developing melanoma. However, these risk factors may lead to melanoma formation through multiple pathways. The investigation into molecular distinctions between individuals who develop melanomas through different avenues may allow the tailoring of public-health messages to the specific population at risk. NCI has designed a study to investigate whether there are signs of a direct transition from common melanocytic nevi to dysplastic nevi to melanoma. The study focuses on the comparison of gene expression from different tissue types (normal skin, nevi, and melanoma) from the same individuals. In addition, the study compares gene expression with protein profile and genotype of the same subjects. Epidemiological and clinical data will be collected as well as photographs of the skin lesions of interest. NCI has already successfully conducted a case-control study and a family study at the Maurizio Bufalini Hospital, Cesena, Italy. The Dermatology Unit of the ?M. Bufalini? Hospital, Cesena, Italy is a reference point for the regions of Southern Emilia-Romagna and Northern Marche, with a population of around 1,000,000. The patients referred to the Bufalini Hospital include more than 85% of the melanoma patients of the area. Dr. Donato Calista at the Bufalini Hospital personally examines the melanoma cases of the Bufalini Hospital. He has collaborated in the past with NCI and has been trained in the recognition of dysplastic nevi and melanoma. Dr. Calista led the field activities of two previous melanoma studies conducted with NCI, and can ensure continuity in the research. In addition, Dr. Calista has acquired expertise in the practical aspects involved in the management of data, photographs, clinical forms, informed consents, and biospecimens, according to NCI standards and needs, and has access to medical records from the Bufalini Hospital, which is crucial for our comparisons. Period of Performance: September 1, 2005 ? August 31, 2006 with one optional year. Dr. Donato Claista at the Bufalini Hospital in Italy is the only source known that can provide the services and expertise needed to full fill the requirements of the NCI. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 1:00 pm EDT on August 15, 2005. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to holdcram@exchange.nih.gov. It is the vendor?s responsibility to call 301-402-4509 or email Malinda Holdcraft, Contract Specialist at the above email address to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must be registered in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Please reference NCI-50119-NG on all correspondence.
- Place of Performance
- Address: Italy
- Country: Italy
- Country: Italy
- Record
- SN00863282-W 20050807/050805211917 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |